Literature DB >> 19883314

Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma.

Kenji Unno1, Ying Zhou, Todd Zimmerman, Leonidas C Platanias, Amittha Wickrema.   

Abstract

There is accumulating evidence that the patterns of altered expression of microRNAs (miRNAs) correlate with distinct types of hematological malignancies. There is also emerging evidence for such miRNAs expression in multiple myeloma (MM), but the identity of the miRNAs that are abnormally expressed in this disease has not been elucidated. In the current study, we examined the miRNAs perturbed in CD138 positive MM cell lines and CD138 positive primary MM cells, using microarray analysis and quantitative real-time PCR. The expression levels in these cells were compared with the expression levels in CD138 positive plasma cells isolated from bone marrows of healthy donors. Our data demonstrate that multiple new miRNAs are commonly up-regulated and down-regulated including a new miRNA cluster, miR-193b-365, composed of two paralogs that were significantly up-regulated in MM. The organization and the sequences of the new miR-193b-365 cluster are highly conserved among vertebrates. Given that dysregulation of miR-193b-365 cluster has not been identified in other hematological malignancies examined to date, our findings suggest that miR-193b-365 cluster is part of the unique miRNA signature in MM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883314      PMCID: PMC2774220          DOI: 10.3109/10428190903221010

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  22 in total

Review 1.  MicroRNAs and cancer.

Authors:  T Dalmay
Journal:  J Intern Med       Date:  2008-02-20       Impact factor: 8.989

2.  A comparison of background correction methods for two-colour microarrays.

Authors:  Matthew E Ritchie; Jeremy Silver; Alicia Oshlack; Melissa Holmes; Dileepa Diyagama; Andrew Holloway; Gordon K Smyth
Journal:  Bioinformatics       Date:  2007-08-25       Impact factor: 6.937

3.  Human microRNA clusters: genomic organization and expression profile in leukemia cell lines.

Authors:  Jia Yu; Fang Wang; Gui-Hua Yang; Fan-Long Wang; Yan-Ni Ma; Zhan-Wen Du; Jun-Wu Zhang
Journal:  Biochem Biophys Res Commun       Date:  2006-08-11       Impact factor: 3.575

4.  Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma.

Authors:  Andrea Rinaldi; Giulia Poretti; Ivo Kwee; Emanuele Zucca; Carlo V Catapano; Maria Grazia Tibiletti; Francesco Bertoni
Journal:  Leuk Lymphoma       Date:  2007-02

Review 5.  Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling.

Authors:  Fabio Petrocca; Andrea Vecchione; Carlo M Croce
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

Review 6.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Authors:  Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

7.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Marco Ladetto; Michael Kuehl; Tiziana Palumbo; Daniela Drandi; Cristian Taccioli; Nicola Zanesi; Hansjuerg Alder; John P Hagan; Reinhold Munker; Stefano Volinia; Mario Boccadoro; Ramiro Garzon; Antonio Palumbo; Rami I Aqeilan; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-26       Impact factor: 11.205

8.  miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia.

Authors:  D L Zanette; F Rivadavia; G A Molfetta; F G Barbuzano; R Proto-Siqueira; W A Silva; R P Falcão; M A Zago
Journal:  Braz J Med Biol Res       Date:  2007-11       Impact factor: 2.590

9.  E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.

Authors:  Fabio Petrocca; Rosa Visone; Mariadele Rapazzotti Onelli; Manisha H Shah; Milena S Nicoloso; Ivana de Martino; Dimitrios Iliopoulos; Emanuela Pilozzi; Chang-Gong Liu; Massimo Negrini; Luigi Cavazzini; Stefano Volinia; Hansjuerg Alder; Luigi P Ruco; Gustavo Baldassarre; Carlo M Croce; Andrea Vecchione
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

10.  Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development.

Authors:  Hiroyuki Tagawa; Kennosuke Karube; Shinobu Tsuzuki; Kouich Ohshima; Masao Seto
Journal:  Cancer Sci       Date:  2007-06-30       Impact factor: 6.716

View more
  25 in total

Review 1.  Modulation of polycystic kidney disease by non-coding RNAs.

Authors:  Harini Ramalingam; Matanel Yheskel; Vishal Patel
Journal:  Cell Signal       Date:  2020-01-23       Impact factor: 4.315

2.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

3.  Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.

Authors:  Weixin Wang; Meghan Corrigan-Cummins; Emily A Barber; Layla M Saleh; Adriana Zingone; Azam Ghafoor; Rene Costello; Yong Zhang; Roger J Kurlander; Neha Korde; Aldo M Roccaro; Irene M Ghobrial; Ola Landgren; Katherine R Calvo
Journal:  J Mol Diagn       Date:  2015-09-30       Impact factor: 5.568

Review 4.  Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Katherine R Calvo; Ola Landgren; Aldo M Roccaro; Irene M Ghobrial
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

5.  Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.

Authors:  Michael A Tessel; Ashley L Benham; Nancy L Krett; Steven T Rosen; Preethi H Gunaratne
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

Review 6.  MicroRNA theragnostics for the clinical management of multiple myeloma.

Authors:  N Ahmad; S Haider; S Jagannathan; E Anaissie; J J Driscoll
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

7.  Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.

Authors:  Dana Ziliak; Eric R Gamazon; Bonnie Lacroix; Hae Kyung Im; Yujia Wen; Rong Stephanie Huang
Journal:  Mol Cancer Ther       Date:  2012-06-29       Impact factor: 6.261

Review 8.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

Review 9.  Promises and challenges of MicroRNA-based treatment of multiple myeloma.

Authors:  P Tagliaferri; M Rossi; M T Di Martino; N Amodio; E Leone; A Gulla; A Neri; P Tassone
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

10.  MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1.

Authors:  Michelle Lenarduzzi; Angela B Y Hui; Nehad M Alajez; Wei Shi; Justin Williams; Shijun Yue; Brian O'Sullivan; Fei-Fei Liu
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.